POAI already did a reverse stock split. This management is the worst because they're scientists, not smart about running public companies. To make matters worse, they're doing this at the same time the global currency/financial system is disintegrating/resetting.
Financial Overview Balance Sheet: Predictive Oncology holds a strong cash position providing approximately 18 months of liquidity and is not currently in need of additional funding. The cash balance is further supported by a large warrant position, the exercise of which may represent an additional source of capital, and combined with the anticipation of increased revenue over the next 2 -3 years, we believe that this cash position can be managed and maintained. Other than normal liabilities, the Company has no debt and maintains a strong equity balance. NASDAQ Deficiency: In May 2022, Predictive Oncology received a price per share deficiency notification. The Company filed an extension to remedy that deficiency in November 2022. The Company now has until May 8, 2023 to attain a minimum $1 trading price per share over ten consecutive trading days. The process of drafting proxies, notifying investors, holding a special shareholder meeting and filing with the SEC is lengthy and proscribed. To manage the notification requirements regarding a potential reverse stock split, the Company must be prepared to act as early as mid-March in order to comply with those reporting requirements. If, at any time during this process, the Company achieves compliance with Nasdaq’s minimum bid price requirement prior to effecting a reverse stock split, there would be no reason to proceed and, instead, the Company would terminate the process. Stock Buy Back: The Company’s Board of Directors believes that the Company value and prospects are not accurately reflected in the trading price of its common stock, and may consider repurchasing shares of its common stock when it is able and advisable to do so in compliance with securities laws. Based on our schedule for filing periodic reports that publicly report our financial condition and results of operations, and specifically with respect to the ongoing Blackout Period, the Company does not expect to be in a position to consider share repurchases until mid-May 2023.
On the other hand, if their product actually works, they might be a unicorn which genuinely revolutionizes cancer treatment across the globe. And this next article is the management (finally) recognizing they are in trouble.
While it won't matter, it's still a good thing: "March 14, 2023: Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development." https://investors.predictive-oncology.com/node/14531/pdf
Market Data 
Markets 
AI
